Antibiotic Resistance in the Elderly: Mechanisms, Risk Factors, and Solutions DOI Creative Commons
Nikolaos Theodorakis, Georgios Feretzakis, Christos Hitas

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(10), P. 1978 - 1978

Published: Sept. 30, 2024

Antibiotic resistance presents a critical challenge in healthcare, particularly among the elderly, where multidrug-resistant organisms (MDROs) contribute to increased morbidity, mortality, and healthcare costs. This review focuses on mechanisms underlying key bacterial pathogens highlights how aging-related factors like immunosenescence, frailty, multimorbidity increase burden of infections from MDROs this population. Novel strategies mitigate include development next-generation antibiotics teixobactin cefiderocol, innovative therapies such as bacteriophage therapy antivirulence treatments, implementation antimicrobial stewardship programs optimize antibiotic use. Furthermore, advanced molecular diagnostic techniques, including nucleic acid amplification tests sequencing, allow for faster more precise identification resistant pathogens. Vaccine development, through approaches multi-epitope vaccines nanoparticle-based platforms, holds promise preventing MDRO elderly. The role machine learning (ML) predicting patterns aiding vaccine is also explored, offering promising solutions personalized treatment prevention By integrating cutting-edge diagnostics, therapeutic innovations, ML-based approaches, underscores importance multidisciplinary efforts address global aging populations.

Language: Английский

The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials DOI Creative Commons
Helen J. Stacey, Steven De Soir, Joshua D. Jones

et al.

Antibiotics, Journal Year: 2022, Volume and Issue: 11(10), P. 1340 - 1340

Published: Sept. 30, 2022

Trials of phage therapy have not consistently reported efficacy. This contrasts with promising efficacy rates from a sizeable and compelling body observational literature. systematic review explores the reasons why many trials demonstrated Four electronic databases were systematically searched for safety and/or therapy. Sixteen included, in which 378 patients received phage. These divided into historical (pre-2000; N = 3; n 76) modern (post-2000; 13; 302) trials. All 13 concluded that was safe. Six exclusively Seven investigated both efficacy; observed two. Two three did comment on safety, while adverse effects third likely reflected use preparations contaminated bacterial debris. None contained evidence The is For to be therapeutic amount right phage(s) must delivered place treat infections containing enough susceptible cells. fulfilled one or more elements this principle.

Language: Английский

Citations

58
Bacteriophage and Bacterial Susceptibility, Resistance, and Tolerance to Antibiotics DOI Creative Commons
Qingquan Chen, Tejas Dharmaraj, Pamela C. Cai

et al.

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(7), P. 1425 - 1425

Published: July 7, 2022

Bacteriophages, viruses that infect and replicate within bacteria, impact bacterial responses to antibiotics in complex ways. Recent studies using lytic bacteriophages treat infections (phage therapy) demonstrate phages can promote susceptibility chemical phage/antibiotic synergy is possible. However, both lysogenic contribute antimicrobial resistance. In particular, some mediate the horizontal transfer of antibiotic resistance genes between bacteria via transduction other mechanisms. addition, chronic infection filamentous tolerance, ability persist face antibiotics. serve as structural elements biofilms prevent penetration Over time, these contributions tolerance favor selection clones. Here, we review recent insights into bacteriophage susceptibility, resistance, tolerance. We discuss mechanisms involved effects address their on fitness.

Language: Английский

Citations

54
Phage Products for Fighting Antimicrobial Resistance DOI Creative Commons

Yuanling Huang,

Wenhui Wang,

Zhihao Zhang

et al.

Microorganisms, Journal Year: 2022, Volume and Issue: 10(7), P. 1324 - 1324

Published: June 30, 2022

Antimicrobial resistance (AMR) has become a global public health issue and antibiotic agents have lagged behind the rise in bacterial resistance. We are searching for new method to combat AMR phages viruses that can effectively fight infections, which renewed interest as alternatives with their specificity. Large phage products been produced recent years AMR. Using “one health” approach, this review summarizes used plant, food, animal, human health. In addition, advantages disadvantages future perspectives development of therapy an alternative also discussed review.

Language: Английский

Citations

45
Use of Phages to Treat Antimicrobial-Resistant Salmonella Infections in Poultry DOI Creative Commons
Md Abu Sayem Khan, Sabita Rezwana Rahman

Veterinary Sciences, Journal Year: 2022, Volume and Issue: 9(8), P. 438 - 438

Published: Aug. 18, 2022

is one of the most common bacterial infections that impacts both human health and poultry production. Although antibiotics are usually recommended for treating

Language: Английский

Citations

42
A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes DOI
Sabrina I. Green,

Justin R. Clark,

Haroldo Hernandez Santos

et al.

Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: 77(8), P. 1079 - 1091

Published: June 3, 2023

Abstract Background Antimicrobial resistance (AMR) is undermining modern medicine, a problem compounded by bacterial adaptation to antibiotic pressures. Phages are viruses that infect bacteria. Their diversity and evolvability offer the prospect of their use as therapeutic solution. Reported outcomes customized phage therapy for patients with difficult-to-treat antimicrobial resistant infections. Methods We retrospectively assessed 12 cases from production center. were screened, purified, sequenced, characterized, Food Drug Administration–approved via IND (investigational new drug) compassionate-care route. Outcomes favorable or unfavorable microbiologic clinical standards. Infections device-related systemic. Other experiences such time treatment, synergy, immune responses recorded. Results Fifty requests received. Customized phages generated patients. After 42% (5/12) showed eradication 58% (7/12) improvement, two-thirds all (66%) showing responses. No major adverse reactions observed. Antibiotic-phage synergy in vitro was observed most cases. Immunological neutralization reported 5 Several complicated secondary Complete characterization (morphology, genomics, activity) (methods, sterility, endotoxin tests) reported. Conclusions safe yielded microbiological A center pipeline dedicated tailoring against patient's specific AMR infection may be viable option where standard treatment has failed.

Language: Английский

Citations

37
The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria DOI Creative Commons

Ka Mun Chung,

Sue C. Nang, Swee-Seong Tang

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(10), P. 1347 - 1347

Published: Sept. 24, 2023

Given the urgency due to rapid emergence of multidrug-resistant (MDR) bacteria, bacteriophages (phages), which are viruses that specifically target and kill rising as a potential alternative antibiotics. In recent years, researchers have begun elucidate safety aspects phage therapy with aim ensuring safe effective clinical applications. While has generally been demonstrated be tolerable among animals humans, current research on monitoring lacks sufficient consistent data. This emphasizes critical need for standardized assessment ensure more reliable evaluation its profile. Therefore, this review aims bridge knowledge gap concerning treating MDR bacterial infections by covering various involving applications, including preparation, administration, implications human health environment.

Language: Английский

Citations

33
Advancements in bacteriophage therapies and delivery for bacterial infection DOI Creative Commons
Hannah Durr,

Nic D. Leipzig

Materials Advances, Journal Year: 2023, Volume and Issue: 4(5), P. 1249 - 1257

Published: Jan. 1, 2023

Having co-evolved with bacteria over hundreds of millions years, bacteriophage are effective killers specific bacterial hosts. Therefore, phage therapies for infection a promising treatment avenue, can provide solution antibiotic resistant infections, and have specified targeting infectious while allowing the natural microbiome to survive which systemic antibiotics often wipe out. Many phages well studied genomes that be modified change target, widen target range, or mode action killing Phage delivery also designed increase efficacy treatment, including encapsulation

Language: Английский

Citations

31
Application of Phage Therapy in a Case of a Chronic Hip-Prosthetic Joint Infection due toPseudomonas aeruginosa: An Italian Real-Life Experience andIn VitroAnalysis DOI Creative Commons
Novella Cesta, Marco Pini, Tiziana Mulas

et al.

Open Forum Infectious Diseases, Journal Year: 2023, Volume and Issue: 10(2)

Published: Feb. 1, 2023

Abstract Background Prosthetic joint infection (PJI) caused by Pseudomonas aeruginosa represents a severe complication in orthopedic surgery. We report the case of patient with chronic PJI from P. successfully treated personalized phage therapy (PT) combination meropenem. Methods A 62-year-old woman was affected right hip prosthesis since 2016 . The Pa53 (I day 10 mL q8h, then 5 q8h via drainage for 2 weeks) association meropenem (2gr q12h iv) after surgical procedure. 2-year clinical follow up performed. An vitro bactericidal assay alone and against 24-hour-old biofilm bacterial isolate also carried out. Results No adverse events were observed during PT. Two years suspension, there no signs relapse, marked leukocyte scan showed pathological uptake areas. In studies that minimum eradicating concentration 8 µg/mL. eradication at 24 hours incubation phages (108 plaque-forming units [PFU]/mL). However, addition suberadicating (1 µg/mL) to lower titer (103 PFU/mL) resulted synergistic incubation. Conclusions Personalized PT, meropenem, found be safe effective infection. These data encourage development aimed evaluating efficacy PT as an adjunct antibiotic persistent infections.

Language: Английский

Citations

27
Gut virome in inflammatory bowel disease and beyond DOI Creative Commons
Hein M. Tun, Ye Peng, Luca Massimino

et al.

Gut, Journal Year: 2023, Volume and Issue: 73(2), P. 350 - 360

Published: Nov. 10, 2023

The gut virome is a dense community of viruses inhabiting the gastrointestinal tract and an integral part microbiota. coexists with other components microbiota host in dynamic equilibrium, serving as key contributor to maintenance intestinal homeostasis functions. However, this equilibrium can be interrupted certain pathological states, including inflammatory bowel disease, causing dysbiosis that may participate disease pathogenesis. Nevertheless, whether causal or bystander event requires further clarification.

Language: Английский

Citations

27
Photoactive MOF-Derived Bimetallic Silver and Cobalt Nanocomposite with Enhanced Antibacterial Activity DOI
Doyun Kim, Kun Woo Park, Jung Tae Park

et al.

ACS Applied Materials & Interfaces, Journal Year: 2023, Volume and Issue: 15(19), P. 22903 - 22914

Published: March 30, 2023

Conventional antibiotic-based treatment of bacterial infections remains one the most difficult challenges in medicine because threat multidrug resistance caused by indiscriminate abuse. To solve these problems, it is essential to develop an effective antibacterial agent that can be used at a small dose while minimizing occurrence multiple resistance. Metal–organic frameworks (MOFs), which are hyper-porous hybrid materials containing metal ions linked organic ligands, have recently attracted attention their strong activity through metal-ion release, unlike conventional antibiotics. In this study, we developed photoactive MOF-derived cobalt–silver bimetallic nanocomposite (Ag@CoMOF) simply depositing silver nanoparticles on cobalt-based MOF nanoscale galvanic replacement. The structure continuously releases (i.e., Ag and Co ions) aqueous phase exhibits photothermal conversion effect nanoparticles, accompanied rapid temperature increase 25–80 °C under near-infrared (NIR) irradiation. Using MOF-based nanocomposite, superior activities were achieved 22.1-fold for Escherichia coli 18.3-fold Bacillus subtilis enhanced inhibition growth liquid culture environment compared with generally chemical addition, confirmed synergistic enhancement ability induced NIR-triggered heating membrane disruption even when using amount nanocomposites. We envision novel nanostructures will replace traditional antibiotics circumvent present new approach antibiotic development.

Language: Английский

Citations

26